Decreased Expression of the CD57 Molecule in T Lymphocytes of Patients with Chronic Fatigue Syndrome
The chronic fatigue syndrome (CFS) is characterized by a prolonged incapacitating fatigue, headaches, sleep disturbances, and decreases in cognition, besides alterations in other physiological functions. At present, no specific biological markers have been described in this pathology. In the present study, we analyzed in lymphocytes the CD57 expression for the diagnosis of CFS, evaluating both the percentage of blood lymphocytes expressing CD57 and the average amount of the molecule expressed per cell. The study demonstrated a marked and significant decrease in the expression of CD57 in lymphocytes of CFS patients regarding healthy controls. In T lymphocytes, the decrease was significant both in the percentage of cells expressing CD57 (7.5 ± 1.2 vs 13.3 ± 1.6, p = 0.024) and in a more relevant way in the amount of CD57 molecule expressed per cell (331 ± 59 vs 1003 ± 104, p ≤ 0.0001). In non-T lymphocytes, the decrease was significant only in the amount of CD57 expressed per cell (379 ± 114 vs 691 ± 95, p = 0.007). The study of CD57 antigen in blood lymphocytes is a useful marker that could cooperate in the diagnosis of CFS patients. Its decrease in T lymphocytes provides most valuable results than the results in other lymphocyte subpopulations.
KeywordsChronic fatigue syndrome CD57
Chronic fatigue syndrome
We thank I. Ródenas and M. Ruiz for their technical collaboration in the development of the work. The present study was selected and supported by the research commission of the Hospital General Universitario de Ciudad Real.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Moss-Morris R, Deary V, Castell B (2013) Chronic fatigue syndrome. In: Handbook of clinical neurology. 110:303–314. https://doi.org/10.1016/B978-0-444-52901-5.00025-3
- 3.Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine (2015) Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. National Academies Press, Washington, D.C. Available from: https://www.ncbi.nlm.nih.gov/books/NBK274235. https://doi.org/10.17226/19012
- 4.Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD (2017) Trends in the incidence of chronic fatigue syndrome and fibromyalgia in the UK, 2001–2013: a clinical practice research datalink study. J R Soc Med 110:231–244. https://doi.org/10.1177/0141076817702530 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, Klimas NG, Marshall-Gradisnik SM (2011) Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 9:81. https://doi.org/10.1186/1479-5876-9-81 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Cabrera CM, Urra JM, Alfaya T, Roca FDL, Feo-Brito F (2014) Expression of Th1, Th2, lymphocyte trafficking and activation markers on CD4+ T-cells of Hymenoptera allergic subjects and after venom immunotherapy. Mol Immunol 62:178–185. https://doi.org/10.1016/j.molimm.2014.06.023 CrossRefPubMedGoogle Scholar
- 17.Montoya JG, Holmes TH, Anderson JN, Maecker HT, Rosenberg-Hasson Y, Valencia IJ, Chu L, Younger JW et al (2017) Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci U S A 114:E7150–E7158. https://doi.org/10.1073/pnas.1710519114 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Curriu M, Carrillo J, Massanella M, Rigau J, Alegre J, Puig J, Garcia-Quintana AM, Castro-Marrero J et al (2013) Screening NK-, B- and T-cell phenotype and function in patients suffering from chronic fatigue syndrome. J Transl Med 11:68. https://doi.org/10.1186/1479-5876-11-68 CrossRefPubMedPubMedCentralGoogle Scholar